Passage Bio receives rare paediatric disease designation for PBGM01 for patients with GM1 gangliosidosis

Passage Bio

21 May 2020 - PBGM01 to enter the clinic in fourth quarter of 2020.

Passage Bio today announced the U.S. FDA has granted rare paediatric disease designation to PBGM01 broadly for the treatment of GM1 gangliosidosis. 

PBGM01 is an AAV-delivery gene therapy currently being developed for the treatment of infantile GM1 gangliosidosis and has previously been granted orphan drug designation.

Read Passage Bio press release

Michael Wonder

Posted by:

Michael Wonder